ASCO GU 2018 Prostate Cancer
Viewing 36-55 of 88 articles
ASCO GU 2018: Debate: Is there Evidence for Local treatment in Patients with Newly Diagnosed Metastatic Disease?
ASCO GU 2018: Impact Of Statins On Outcomes In Patients With mCRPC: COU-AA-301 and COU-AA-302 Trials
ASCO GU 2018: Radical Prostatectomy in Metastatic Castration-resistant Prostate Cancer: Feasibility, Safety, and Quality of Life Outcomes
ASCO GU 2018: Effects Of a 6-month Moderate-intensity Exercise Program on Metabolic Parameters and Bone Mineral Density in Men on Androgen Deprivation Therapy for Prostate Cancer
ASCO GU 2018: Outcomes in Patients with Advanced Prostate Cancer And Inactivating Germline Mutations in BRCA2 or ATM
ASCO GU 2018: Incorporating Genomics Into the Management of Systemic Therapy: Advances and Practicality
ASCO GU 2018: Why are Low-risk Prostate Cancers (Pca) Treated Aggressively? A Population-based Cohort Analysis
ASCO GU 2018: A National Survey of Radiation Oncologists and Urologists on Active Surveillance for Low-risk Prostate Cancer
ASCO GU 2018: When Can Active Surveillance Be Less Active? Prediction of Long-term Non-reclassification for Men with Low-risk Prostate Cancer
ASCO GU 2018: Can free PSA be used as a biomarker in biochemical recurrence after surgery to predict CRPC?
ASCO GU 2018: Radium-223 Retreatment in an International, Open-label, Phase I/II Study in Patients with CRPC and Bone Metastases: 2-year Follow-up
ASCO GU 2018: Abiraterone acetate plus prednisone 5 mg daily in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase III trial
ASCO GU 2018: Indirect Treatment Comparison of Abiraterone Acetate Plus Prednisone and Docetaxel on Patient-reported Outcomes in Metastatic Castration-naïve Prostate Cancer (mCNPC)
ASCO GU 2018: Overall Survival of Patients with Metastatic Prostate Cancer Starting ADT with Degarelix, A Gonadotropin-releasing Hormone Antagonist